argenex (NASDAQ:ARGX) Upgraded at Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft upgraded shares of argenex (NASDAQ:ARGX) from a hold rating to a buy rating in a research note issued to investors on Tuesday morning, Marketbeat Ratings reports.

A number of other brokerages have also issued reports on ARGX. Robert W. Baird raised their target price on shares of argenex from $858.00 to $867.00 and gave the stock a “neutral” rating in a research report on Friday, February 27th. HC Wainwright upped their price target on shares of argenex from $915.00 to $940.00 and gave the company a “buy” rating in a research report on Friday, February 27th. Wells Fargo & Company lowered their price objective on shares of argenex from $1,317.00 to $1,247.00 and set an “overweight” rating on the stock in a research report on Friday, February 27th. Weiss Ratings reissued a “hold (c)” rating on shares of argenex in a research report on Wednesday, January 21st. Finally, Wedbush restated an “outperform” rating and issued a $1,000.00 price objective on shares of argenex in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $999.22.

argenex Stock Down 2.6%

Shares of NASDAQ ARGX opened at $708.85 on Tuesday. The business has a 50-day moving average price of $806.79 and a 200 day moving average price of $815.81. The stock has a market cap of $43.86 billion, a PE ratio of 36.31, a price-to-earnings-growth ratio of 1.20 and a beta of 0.38. argenex has a 52-week low of $510.05 and a 52-week high of $934.62.

argenex (NASDAQ:ARGX) last released its quarterly earnings results on Thursday, February 26th. The company reported $8.02 EPS for the quarter, topping the consensus estimate of $6.05 by $1.97. argenex had a return on equity of 38.51% and a net margin of 30.42%.The company had revenue of $1.32 billion for the quarter, compared to analyst estimates of $1.30 billion. Sell-side analysts anticipate that argenex will post 3.13 earnings per share for the current year.

Institutional Trading of argenex

Several hedge funds have recently made changes to their positions in ARGX. M&T Bank Corp boosted its holdings in argenex by 20,977.7% in the 4th quarter. M&T Bank Corp now owns 778,610 shares of the company’s stock valued at $654,772,000 after purchasing an additional 774,916 shares in the last quarter. Sands Capital Management LLC raised its stake in shares of argenex by 2,046.6% during the 4th quarter. Sands Capital Management LLC now owns 356,870 shares of the company’s stock worth $300,110,000 after buying an additional 340,245 shares in the last quarter. Invesco Ltd. raised its stake in shares of argenex by 390.4% during the 4th quarter. Invesco Ltd. now owns 416,408 shares of the company’s stock worth $350,178,000 after buying an additional 331,489 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of argenex by 80.1% in the 3rd quarter. Wellington Management Group LLP now owns 729,986 shares of the company’s stock valued at $538,408,000 after buying an additional 324,653 shares during the period. Finally, Two Sigma Investments LP lifted its holdings in shares of argenex by 570.3% in the 3rd quarter. Two Sigma Investments LP now owns 294,160 shares of the company’s stock valued at $216,961,000 after buying an additional 250,278 shares during the period. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.